Cubit Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 27853.34%
About Cubit Formulations
Cubit Formulations Private Limited (CFPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 March 2020 (Four years and 11 months 11 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Priyanka Agrawal, Ashok Agrawal, and Prabhat Agrawal serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ2020PTC113141
- Company No.
113141
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Cubit Formulations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanka Agrawal  | Director | 13-Mar-2020 | Current |
| Ashok Agrawal | Director | 13-Mar-2020 | Current |
| Prabhat Agrawal | Director | 13-Mar-2020 | Current |
Financial Performance of Cubit Formulations.
Cubit Formulations Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Cubit Formulations?
In 2021, Cubit Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cubit Lifesciences LlpPriyanka Agrawal, Ashok Agrawal and 1 more are mutual person
Cusan Wellness LlpAshok Agrawal and Prabhat Agrawal are mutual person
- Cubit Medisurge Llp
Prabhat Agrawal is a mutual person
- Cusan Apis Private Limited
Prabhat Agrawal is a mutual person
- Acacia Biotech Limited
Prabhat Agrawal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cubit Formulations?
Unlock and access historical data on people associated with Cubit Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cubit Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cubit Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.